Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 24;29(17):3418–3428. doi: 10.1158/1078-0432.CCR-23-0580

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2023 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 5. Comparison of RECIST and real-world endpoints. A, rwPFS versus PFS-RECIST. rwPFS metrics are compared with PFS determined by RECIST for patients treated with ICIs at MSKCC. B, Difference in TTNT and PFS-I for patients treated with first-line chemotherapy without oncogenic drivers. C, Difference in TTNT and PFS-I for patients with targetable alterations (EGFR, ALK, ROS1, MET) treated with targeted therapies. — Comparison of RECIST and real-world endpoints. A, rwPFS versus PFS-RECIST. rwPFS metrics are compared with PFS determined by RECIST for patients treated with ICIs at MSKCC. B, Difference in TTNT and PFS-I for patients treated with first-line chemotherapy without oncogenic drivers. C, Difference in TTNT and PFS-I for patients with targetable alterations (EGFR, ALK, ROS1, MET) treated with targeted therapies.